🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT06494878
Recruiting Phase 3

The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

NCT06494878 · tracked via the Priya Life Science Canada tracker
Phase
Phase 3
Started
2026-06-04
Last updated
2026-07-27

Condition(s) studied

Venous ThromboembolismPostpartum PeriodAspirinLow Molecular Weight Heparin

Investigational drug(s) / intervention(s)

Aspirin →Low-molecular-weight heparin →

Aspirin: 75-100 mg taken once daily by mouth.

Low-molecular-weight heparin: Low-molecular-weight heparin injections daily as prescribed by the treating physician.

Study summary

The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * ONE (or more) First Order Criterion: 1. Known inherited thrombophilia diagnosed prior to enrolment, regardless of family history of VTE: i. Heterozygous factor V Leiden, or ii. Heterozygous prothrombin gene variant, or iii. Protein C deficiency, or iv. Protein S deficiency, and/or 2. Antepartum immobilization for ≥7 days. Immobilization is defined as bed rest with 90% of waking hours spent in bed at any time during the antepartum period AND/OR TWO (or more) Second Order Criteria: 1. Pre-pregnancy BMI ≥30 kg/m² 2. Smoking in the current pregnancy or within 3 months prior to pregnancy 3. Previous clinical history of superficial vein thrombosis 4. Preeclampsia 5. Current pregnancy ending in stillbirth (pregnancy loss \>20 weeks gestation) 6. Unplanned cesarean delivery (unplanned = not a scheduled cesarean delivery) 7. Small-for-gestational-age infant at time of delivery (\<3rd percentile adjusted for gestational age and sex) 8. Peripartum or postpartum infection (symptoms/signs of infection and documented fever and laboratory evidence of infection with positive blood cultures or an elevated white blood cell count based on local laboratory cutoffs) 9. Postpartum hemorrhage (≥1000 mL of blood loss, regardless of delivery mode) Exclusion Criteria: 1. More than 48 hours since delivery at the time of randomization 2. Received more than 1 dose of LMWH since delivery 3. Need for postpartum LMWH prophylaxis or systemic anticoagulation as judged by their physician and/or local investigator. May include but is not limited to: 1. Documented history of provoked or unprovoked VTE 2. Mechanical heart valve(s) 3. Known antiphospholipid syndrome (APS) 4. Known high-risk inherited thrombophilia i) Antithrombin deficiency, or ii) Homozygous factor V Leiden, or iii) Homozygous prothrombin gene mutation, or iv) More than 1 thrombophilia: any combination of 2 or more: factor V Leiden, prothrombin gene mutation, protein C deficiency, protein S deficiency 4. Need for postpartum ASA as judged by their physician and/or local investigator. May include but is not limited to: 1. Documented history of myocardial infarction 2. Documented history of ischemic stroke or transient ischemic attack (TIA) 5. Active bleeding, excluding normal vaginal bleeding, at the time of randomization 6. Known medical condition as judged by their physician and/or local investigator to be a contraindication to ASA or LMWH including known ASA or LMWH allergy 7. \<18 years of age 8. Unable or declined consent

Primary outcome measure(s)

Trial sites (12)

FacilityCityRegionStatus
Association Hospitalière De Bruxelles Et De Schaerbeek - Centre Hospitalier Universitaire Brugmann Brussels Belgium Not Yet Recruiting
Foothills Medical Centre Calgary Alberta Recruiting
The Ottawa Hospital - General Campus Ottawa Ontario Not Yet Recruiting
Hvidovre Hospital Hvidovre Capital Region Not Yet Recruiting
CHU de Nancy Nancy France Not Yet Recruiting
APHP - Hôpital Port Royal Paris France Not Yet Recruiting
CHU de Saint-Etienne Saint-Etienne France Not Yet Recruiting
CHU de Toulouse Toulouse France Not Yet Recruiting
Rotunda Hospital, RCSI Department of Obstetrics and Gynaecology Dublin Ireland Not Yet Recruiting
UCD Centre for Human Reproduction, The Coombe Hospital Dublin Ireland Not Yet Recruiting
Amsterdam UMC Amsterdam Netherlands Not Yet Recruiting
Medical University of Warsaw Warsaw Poland Not Yet Recruiting

More University of Calgary trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06494878 on ClinicalTrials.gov ↗ ← All trials in Canada